New methods of testing tissue and plasma beyond next-generation sequencing (NGS) could be used to deliver the best ...

Clonal hematopoiesis of indeterminate potential (CHIP) is a known risk factor for coronary artery disease, though its precise role in disease progression continues to emerge. This study leverages ...

The global sales of microbial identification are estimated to be worth USD 4.69 billion in 2025 and anticipated to reach a ...

This insightful review explores key areas of cancer genetic research, focusing on genes that may benefit from ...

Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a clinical-stage leader in regenerative and cellular innovation, today announced the official launch of ...

The study aims to screen 100,000 newborns in England, with over 40 hospitals currently taking part. Caroline Dixon, Senior Research Team Lead Midwifery at Mid Cheshire Hospitals, said: “We’re excited ...

Med Center Health has been named a Center of Excellence (COE) by GO2 for Lung Cancer (GO2). An estimated 237,000 Americans ...

Swiss Rockets, MGI US LLC and Complete Genomics Inc. announced today that they entered into a exclusive license agreement ...

Across conversations on precision oncology, malignant hematology, cellular therapies, and social determinants of health (SDOH ...

New plate-based multiplexing unlocks ultra high-sample and cell-throughput single cell analysis to empower a broad range of ...

Takara Bio Inc. announced Tuesday that it will begin developing reagents for "next-generation sequencing," which will allow large volumes of genetic information to be read rapidly, in collaboration ...

"These results are encouraging, highlighting TET2-mutated clonal hematopoiesis as a potential biomarker to select patients who are more likely to respond to immunotherapy," said Padmanee Sharma, M.D., ...